Trial Profile

A randomized, phase 3, two-armed, parallel group, double blind (patient and outcome assessor blinded), active control, non-inferiority clinical trial to assess the efficacy and safety of Cetuximab bio-similar (Zistdaru Danesh Co. ®) compared to Erbitux (Merck®) in the patients with head and neck squamous cell carcinoma.

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 27 Mar 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetuximab (Primary) ; Diphenhydramine
Indications Head and neck cancer; Laryngeal cancer; Mouth neoplasm; Nasopharyngeal cancer; Oropharyngeal cancer; Pharyngeal neoplasms; Squamous cell cancer
Focus Therapeutic Use

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com